Lista completa de Publicações

@article{Sousa2026,

title = {Head-to-head comparison of 18F-PSMA and 18F-FDG PET/CT in locoregionally advanced head and neck squamous cell carcinoma: a pilot study},

author = {Hádila da Silva Veras Sousa and Victor Cabral Costa Ribeiro Heringer and Matheus Yung Perin and Nájua Abou Arabi Silveira and Simone Kuba and Ligia Traldi Macedo and Gustavo Jacob Lourenço and Carlos Takahiro Chone and Carmino Antônio de Souza and Celso Dario Ramos and Carmen Silvia Passos Lima},

doi = {10.1016/j.bjorl.2026.101863},

issn = {1808-8694},

year  = {2026},

date = {2026-09-00},

urldate = {2026-09-00},

journal = {Brazilian Journal of Otorhinolaryngology},

volume = {92},

number = {5},

publisher = {Elsevier BV},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{vonZuben2026,

title = {The impact of social inequalities on cancer incidence and mortality in a Brazilian City: Data from the population-based cancer registry},

author = {Andrea Paula Bruno von Zuben and Maria do Carmo Ferreira and Marilisa Berti de Azevedo Barros and Juliana Nativo and M. Elvira P. Correa and Carmino Antônio de Souza},

doi = {10.1016/j.canep.2026.103102},

issn = {1877-7821},

year  = {2026},

date = {2026-08-00},

urldate = {2026-08-00},

journal = {Cancer Epidemiology},

volume = {103},

publisher = {Elsevier BV},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Cunha2026,

title = {FDG-PET/CT Demonstrates Superior Detection of Multiorgan Involvement in Paracoccidioidomycosis Compared With Conventional Staging},

author = {Pricila G Cunha and Maria Emilia Seren Takahashi and Raquel S B Stucchi and Mariana Paixão Ribeiro and Thiago F Souza and Carmino Antonio de Souza and Barbara Juarez Amorim and Maria Luiza Moretti and Plinio Trabasso and Celso Dario Ramos},

doi = {10.1093/cid/ciag372},

issn = {1537-6591},

year  = {2026},

date = {2026-06-19},

urldate = {2026-06-19},

publisher = {Oxford University Press (OUP)},

abstract = {<jats:title>Abstract</jats:title>

                  <jats:sec>

                    <jats:title>Background</jats:title>

                    <jats:p>Paracoccidioidomycosis (PCM) is a neglected systemic mycosis in which accurate staging is critical but challenging with conventional methods. This study evaluated 18F-FDG PET/CT compared with standard evaluation for PCM staging and assessed its impact on disease severity classification.</jats:p>

                  </jats:sec>

                  <jats:sec>

                    <jats:title>Methods</jats:title>

                    <jats:p>Thirty-four patients with confirmed PCM (treatment-naïve or with suspected treatment failure) underwent conventional staging and whole-body 18F-FDG PET/CT. Disease severity was classified as mild, moderate, or severe. PET/CT images were analyzed qualitatively and quantitatively (SUVmax, TMLV, TLG).</jats:p>

                  </jats:sec>

                  <jats:sec>

                    <jats:title>Results</jats:title>

                    <jats:p>PET/CT detected more than twice as many lesions as conventional evaluation (150 vs 62; mean 4.4 ± 1.6 vs 1.8 ± 0.9 affected organ systems per patient), with statistically significant superiority for lymph node, pulmonary, and adrenal involvement (McNemar's test, P < .05). PET/CT reclassified 97% of patients as multifocal versus 59% by conventional staging and produced a significant unidirectional shift toward higher severity—the proportion classified as severe increased from 70.6% to 91.2% (P = .016). Patients with suspected treatment failure showed significantly lower TMLV and TLG than treatment-naïve patients (P < .05). Quantitative PET parameters correlated with serological titers and inflammatory markers (P < .05), and PET/CT detected four times as many sites as gallium-67 scintigraphy.</jats:p>

                  </jats:sec>

                  <jats:sec>

                    <jats:title>Conclusions</jats:title>

                    <jats:p>18F-FDG PET/CT systematically reveals greater disease burden than conventional evaluation in PCM, reclassifying most patients toward higher severity with direct implications for treatment duration and follow-up. Where available, it should be considered an important complementary modality for initial disease assessment.</jats:p>

                  </jats:sec>},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Caleffi2026,

title = {Determination of a new gastric cancer mortality predictor based on body composition radiodensity variables},

author = {Mariana Caleffi and Daniela Morais de Holanda Padilha and Vinicius Bassete and Gianni Liveraro and Pedro Henrique Alves and Maria Emilia Seren Takahashi and Leo Victor Kim and Maria Carolina Santos Mendes and Jun Takahashi and José Barreto Campello Carvalheira},

doi = {10.1016/j.clnesp.2026.103132},

issn = {2405-4577},

year  = {2026},

date = {2026-06-00},

urldate = {2026-06-00},

journal = {Clinical Nutrition ESPEN},

volume = {73},

publisher = {Elsevier BV},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{deLima2026,

title = {Protocol for a pilot-randomized trial in newly diagnosed glioblastoma: standard care with or without daily intranasal perillyl alcohol},

author = {Daniela Carneiro de Lima and Axel H. Schönthal and Clóvis Orlando Pereira da Fonseca and Fabiano Reis and Carmen Silvia Passos Lima and Mary Ann Foglio},

doi = {10.1080/14796694.2026.2652540},

issn = {1744-8301},

year  = {2026},

date = {2026-05-03},

urldate = {2026-05-03},

journal = {Future Oncology},

volume = {22},

number = {11},

pages = {1263--1271},

publisher = {Informa UK Limited},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Takahashi2026,

title = {Diagnostic brain-to-liver [18f]fdg uptake ratio predicts survival in multiple myeloma: A retrospective study},

author = {Maria Emilia S. Takahashi and Tiago P. dos Santos and Christopher Cralcev and Eliana Miranda and Marcos Paulo D. S. Silva and Felipe C. Souza and José Barreto C. Carvalheira and Carmino A. de Souza and Celso Dario Ramos},

doi = {10.1007/s00259-026-07844-z},

issn = {1619-7089},

year  = {2026},

date = {2026-03-21},

urldate = {2026-03-21},

journal = {Eur J Nucl Med Mol Imaging},

publisher = {Springer Science and Business Media LLC},

abstract = {<jats:title>Abstract</jats:title>

                  <jats:sec>

                    <jats:title>Purpose</jats:title>

                    <jats:p>[¹⁸F]FDG PET/CT has been widely used in oncology for diagnosis and treatment monitoring. Reduced cerebral [¹⁸F]FDG uptake has been observed in patients with disseminated malignancies, potentially associated with the Warburg effect and elevated lactate levels. This study investigated the prognostic relevance of the brain-to-liver [¹⁸F]FDG uptake ratio (BLR) in MM patients who underwent PET/CT at diagnosis.</jats:p>

                  </jats:sec>

                  <jats:sec>

                    <jats:title>Methods</jats:title>

                    <jats:p>BLR was calculated as the ratio between the mean standardized uptake value (SUV) of the whole brain and that of the liver. A total of 72 patients were retrospectively included in the study (58% male; median age 65 years (IQR55;70); 67% were classified as ISS stage III).</jats:p>

                  </jats:sec>

                  <jats:sec>

                    <jats:title>Results</jats:title>

                    <jats:p>

                      BLR, as a continuous variable, showed a statistically significant difference between groups according to sex (

                      <jats:italic>p</jats:italic>

                       = 0.004), overweight status (

                      <jats:italic>p</jats:italic>

                       = 0.005), and ISS stage (

                      <jats:italic>p</jats:italic>

                       = 0.03), and was negatively correlated with β₂-microglobulin (

                      <jats:italic>r</jats:italic>

                      = − 0.42,

                      <jats:italic>p</jats:italic>

                       < 0.001). With a median follow-up of 23 months (IQR 8; 65), 74% patients had died from MM-related causes. Patients with BLR > 2.7 demonstrated superior 60-month overall survival (52%vs.10%,

                      <jats:italic>p</jats:italic>

                       = 0.002) and progression-free survival (19%vs.3%,

                      <jats:italic>p</jats:italic>

                       = 0.003), respectively. Multivariate Cox regression confirmed BLR (HR 1.86 95%CI: 1.03–3.33,

                      <jats:italic>p</jats:italic>

                       = 0.038 (OS); HR 1.93 95%CI: 1.13–3.29,

                      <jats:italic>p</jats:italic>

                       = 0.016 (PFS))as an independent factor and the use of autologous hematopoietic cell transplantation (HCT) as consolidation for both OS and PFS. In addition, ISS stage III was also a prognostic factor for OS.

                    </jats:p>

                  </jats:sec>

                  <jats:sec>

                    <jats:title>Conclusion</jats:title>

                    <jats:p>Higher brain-to-liver [¹⁸F]FDG uptake ratio (> 2.7) at diagnosis predicts better clinical outcomes in multiple myeloma. BLR is significantly associated with established clinical markers of tumor burden in multiple myeloma. These findings suggest that BLR is a feasible and reproducible metric with potential prognostic value in multiple myeloma.</jats:p>

                  </jats:sec>},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Social inequalities in cancer incidence and mortality in Campinas, Brazil: a decade of population-based registry data (2010-2019)},

author = {Andrea Paula Bruno von Zuben and Carmino Antonio de Souza },

year  = {2026},

date = {2026-01-20},

urldate = {2026-01-20},

journal = {International Journal of Annals Medical and Health Science},

volume = {4},

issue = {1},

pages = {1-2},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Torricelli2026,

title = {Insights from PSMAfore: impact on health-related quality of life},

author = {Caroline Torricelli and Natália Tobar and André Sasse and Elba Etchebehere},

doi = {10.21037/tau-2025-aw-750},

issn = {2223-4691},

year  = {2026},

date = {2026-01-00},

urldate = {2026-01-00},

journal = {Transl Androl Urol},

volume = {15},

number = {1},

pages = {3--3},

publisher = {AME Publishing Company},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Carron2026,

title = {CTLA-4 and TNFRSF1B genetic variants in clinicopathological aspects and outcome of cutaneous melanoma},

author = {Juliana Carron and Ana Maria Castro Ferreira and Bruna Fernandes Carvalho and Gustavo Jacob Lourenço and Carmen Silvia Passos Lima},

doi = {10.1097/cmr.0000000000001108},

issn = {1473-5636},

year  = {2026},

date = {2026-00-00},

urldate = {2026-00-00},

volume = {36},

number = {4},

pages = {263--273},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

                    <jats:title/>

                    <jats:p>

                      Cutaneous melanoma is the most aggressive form of skin cancer, influenced by environmental and genetic factors, particularly immune-related genes like cytotoxic T-lymphocyte-associated protein 4 (

                      <jats:italic toggle="yes">CTLA-4</jats:italic>

                      ) and

                      <jats:italic toggle="yes">TNFRSF1B</jats:italic>

                      . We investigated the association of inherited single nucleotide variants in

                      <jats:italic toggle="yes">CTLA-4</jats:italic>

                      (rs11571316, rs62182595, rs11571315, and rs4553808) and

                      <jats:italic toggle="yes">TNFRSF1B</jats:italic>

                      (rs3397, rs1061622, rs1061624, and rs1061628) with clinicopathological aspects and survival of 428 cutaneous melanoma patients. Carriers of

                      <jats:italic toggle="yes">CTLA-4</jats:italic>

                      rs4553808 AG/GG plus

                      <jats:italic toggle="yes">TNFRSF1B</jats:italic>

                      rs3397 TC/CC genotypes were younger at diagnosis. The

                      <jats:italic toggle="yes">CTLA-4</jats:italic>

                      rs4553808 AA plus

                      <jats:italic toggle="yes">TNFRSF1B</jats:italic>

                      rs1061624 GG genotypes were more common in male than female patients.

                      <jats:italic toggle="yes">CTLA-4</jats:italic>

                      rs4553808 AA or rs62182595 GG plus

                      <jats:italic toggle="yes">TNFRSF1B</jats:italic>

                      rs1061624 GG were more frequent among patients with tumors on the head, neck, and trunk. Patients older than 54 years with

                      <jats:italic toggle="yes">CTLA-4</jats:italic>

                      rs11571316 GG and

                      <jats:italic toggle="yes">TNFRSF1B</jats:italic>

                      rs3397 TT had a 3.04-times greater chance of progression to death because of tumor effects. Patients with head, neck, and trunk cutaneous melanoma carrying

                      <jats:italic toggle="yes">CTLA-4</jats:italic>

                      rs4553808 AG/GG and

                      <jats:italic toggle="yes">TNFRSF1B</jats:italic>

                      rs1061624 GA/AA had a 2.30-times greater chance of recurrence, progression, or tumor-related death. Patients with head, neck, and trunk cutaneous melanoma carrying

                      <jats:italic toggle="yes">CTLA-4</jats:italic>

                      rs4553808 AG/GG and

                      <jats:italic toggle="yes">TNFRSF1B</jats:italic>

                      rs1061624 GA/AA, and

                      <jats:italic toggle="yes">CTLA-4</jats:italic>

                      rs62182595 GA/AA and

                      <jats:italic toggle="yes">TNFRSF1B</jats:italic>

                      rs1061624 GA/AA genotypes had a 2.97- and 2.75-times greater chance of progression to death because of tumor effects, respectively. These findings suggest immune modulation linked to these single nucleotide variants may facilitate cutaneous melanoma progression and highlight the potential for immunotherapeutic strategies in genetically predisposed patients.

                    </jats:p>

                  </jats:sec>},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Souza2025,

title = {Brazilian profile of Radium-223 in metastatic prostate cancer: a multicentric, retrospective study},

author = {Stephan Souza and Felipe Ribeiro and Ana Brito and Thaís Minekawa and Flávia Lopes and Sumara Matedi and Renata Fockink and Dalton Anjos and Gustavo Gomes and Laura Silva and Mariana Camacho and Allan Santos and Whemberton Araújo and Ana Teixeira and Raul Martins and Adelina Sanches and Nilton Hanaoka and Rafael Tavares and Felipe Villela-Pedras and Felipe Mourato and Caroline Torricelli and Thiago Alves and Marcelo Tavares and Mariana Lima and André Moraes and André Sasse and Paulo Almeida and Elba Etchebehere},

doi = {10.1186/s41824-025-00245-9},

issn = {3005-074X},

year  = {2025},

date = {2025-12-00},

urldate = {2025-12-00},

journal = {EJNMMI Rep.},

volume = {9},

number = {1},

publisher = {Springer Science and Business Media LLC},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Genaro2025b,

title = {Interpretable Artificial Neural Network Models for Predicting Anti-Adalimumab Immune Complex and Serum Drug Level in Crohn’s Disease: A Proof-of-Concept Study},

author = {Livia Moreira Genaro and Juliana Carron and Gustavo Jacob Lourenço and Cristiane Kibune Nagasako and Glaucia Fernanda Soares Rupert Reis and Michel Gardere Camargo and Priscilla de Sene Portel Oliveira and Carmen Silvia Passos Lima and Maria de Lourdes Setsuko Ayrizono and Anibal Tavares de Azevedo and Raquel Franco Leal},

doi = {10.3390/pharmaceutics17121536},

issn = {1999-4923},

year  = {2025},

date = {2025-12-00},

urldate = {2025-12-00},

journal = {Pharmaceutics},

volume = {17},

number = {12},

publisher = {MDPI AG},

abstract = {<jats:p>Background: The development of anti-drug antibodies (ADAs) and resulting immune complexes are key mechanisms behind the secondary loss of response to adalimumab in Crohn’s disease (CD). Despite their clinical importance, routine immunogenicity assays are limited, underscoring the need for alternative predictive approaches. Objective: This study aimed to develop interpretable artificial neural network (ANN) models to predict immune complex formation and estimate serum adalimumab levels using routinely available clinical and laboratory data from CD patients. Methods: A prospective analysis was performed on 58 CD patients on maintenance adalimumab. Immune complexes and serum adalimumab were measured via ELISA and lateral flow assays. ANN and ensemble regression models were trained on demographic, clinical, and inflammatory data, with performance evaluated by five-fold cross-validation. Interpretability was enhanced using Garson’s algorithm and permutation importance. Results: The ANN-based classification model accurately predicted ADA immune complex formation, achieving an accuracy of 77.47% and an area under the curve (AUC) of 82.63%. The main predictive variables included extraintestinal manifestations, perianal disease, disease behavior, and age at diagnosis. For estimating serum adalimumab levels measured by ELISA, the model performed modestly (accuracy 59.89%, AUC 79.72%), incorporating factors such as Montreal classification, perianal disease, C-reactive protein, immunosuppressant use, and disease duration. Conclusions: Interpretable ANN models robustly predict anti-adalimumab immune complexes and, to a lesser extent, serum adalimumab, using clinically available data, including perianal disease. This proof-of-concept study is limited by the relatively small, single-center dataset (n = 58), which may affect model generalizability and increase the risk of overfitting. External validation in larger and multicenter cohorts is required before clinical implementation.</jats:p>},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Ramos2025b,

title = {Quantification in Clinical Nuclear Medicine: A Language Before a Number},

author = {Celso Dario Ramos},

doi = {10.1097/rlu.0000000000006145},

issn = {1536-0229},

year  = {2025},

date = {2025-10-30},

urldate = {2025-10-30},

journal = {Clinical Nuclear Medicine},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Ramos2025,

title = {Redefining Nuclear Medicine: “Biodistribution” Should Be the Core Concept},

author = {Celso Dario Ramos},

doi = {10.2967/jnumed.125.270245},

issn = {2159-662X},

year  = {2025},

date = {2025-09-00},

urldate = {2025-09-00},

journal = {J Nucl Med},

volume = {66},

number = {9},

pages = {1498--1498},

publisher = {Society of Nuclear Medicine},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Carrilho2025b,

title = {Prognostic impact of low muscularity in metastatic and recurrent head and neck cancer: Insights from C3-based assessments},

author = {Larissa Ariel Oliveira Carrilho and Livia Dias Guerra and Rafaella Caroline de Lellis Moreira and Fabiana Lascala Juliani and Fernanda Silva Santos and Daniela Morais de Holanda Padilha and Fabíola Furtuoso Zaperlão and Sandra Regina Branbilla and Vivian Naomi Horita and Davi Magalhães Leite Novaes and Lígia Moraes Antunes-Correa and Carmem Silvia Passos Lima and Maria Carolina Santos Mendes and José Barreto Campello Carvalheira},

doi = {10.1016/j.clnesp.2025.06.029},

issn = {2405-4577},

year  = {2025},

date = {2025-08-00},

urldate = {2025-08-00},

journal = {Clinical Nutrition ESPEN},

volume = {68},

pages = {767--773},

publisher = {Elsevier BV},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Carrilho2025,

title = {Adipose tissue characteristics as a new prognosis marker of patients with locally advanced head and neck cancer},

author = {Larissa Ariel Oliveira Carrilho and Fabiana Lascala Juliani and Rafaella Caroline de Lellis Moreira and Livia Dias Guerra and Fernanda Silva Santos and Daniela Morais de Holanda Padilha and Sandra Regina Branbilla and Vivian Naomi Horita and Davi Magalhães Leite Novaes and Lígia Macedo Antunes-Correa and Carmem Silvia Passos Lima and Maria Carolina Santos Mendes and José Barreto Campello Carvalheira},

doi = {10.3389/fnut.2025.1472634},

issn = {2296-861X},

year  = {2025},

date = {2025-03-14},

urldate = {2025-03-14},

journal = {Front. Nutr.},

volume = {12},

publisher = {Frontiers Media SA},

abstract = {<jats:sec><jats:title>Background</jats:title><jats:p>Patients with head and neck cancer (HNC) are at increased risk of malnutrition due to the presence of tumor and treatments. Body composition is a prognostic factor in these patients. However, the relationship between adipose tissue characteristics and survival in HNC is still unclear.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To evaluate the associations of adiposity, the radiodensity of adipose tissue and muscularity with the prognosis of patients with locally advanced HNC undergoing to chemoradiotherapy.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This retrospective study included 132 patients diagnosed with locally advanced HNC. Body composition assessment was performed using computed tomography (CT) images at the level of the third cervical vertebra (C3). The total adipose tissue radiodensity (TATR), the total adipose tissue index (TATI) and skeletal muscle index (SMI) were evaluated. The primary outcome was overall survival (OS).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Patients in the highest TATI tertile had a lower risk of mortality when compared to those in the lowest tertile, HR: 0.56, 95% confidence Interval (CI): 0.32–0.96; <jats:italic>p</jats:italic> = 0.039. The highest TATR tertile was not associated with death. Patients with greater adiposity had a higher median survival compared to patients with medium and lower TATI (<jats:italic>p</jats:italic> = 0.0193). Individuals with lower TATI had lower energy intake than patients with higher TATI (<jats:italic>p</jats:italic> = 0.03). Additionally, patients with low muscularity had worse OS in the multivariable analysis (HR: 1.77, 95% CI: 1.01–3.07; <jats:italic>p</jats:italic> = 0.044).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In patients with locally advanced HNC, our findings underscore the significance of elevated adiposity, beyond maintained muscularity, as independent protective factors for overall survival. Our study highlights the critical importance of assessing body composition and initiating early nutritional interventions to improve the prognosis of these patients.</jats:p></jats:sec>},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{deMenezesPereira2025,

title = {Antibacterial profile and antiproliferative activities over human tumor cells of new silver(I) complexes containing two distinct trifluoromethyl uracil isomers},

author = {Gabriele de Menezes Pereira and Julia H. Bormio Nunes and Vinicius Souza Macedo and Douglas Henrique Pereira and Kaio Eduardo Buglio and Daniele D. Affonso and Ana Lucia T.G. Ruiz and João Ernesto de Carvalho and Silmara Cristina L. Frajácomo and Wilton R. Lustri and Carmen Silvia Passos Lima and Fernando R.G. Bergamini and Alexandre Cuin and Norberto Masciocchi and Pedro Paulo Corbi},

doi = {10.1016/j.jinorgbio.2024.112752},

issn = {0162-0134},

year  = {2025},

date = {2025-01-00},

urldate = {2025-01-00},

journal = {Journal of Inorganic Biochemistry},

volume = {262},

publisher = {Elsevier BV},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Genaro2025,

title = {Therapeutic drug monitoring and immunogenetic factors associated with the use of adalimumab in Crohn’s disease patients},

author = {Livia Moreira Genaro and Juliana Carron and Marina Moreira de Castro and Ana Paula Menezes de Freitas Franceschini and Gustavo Jacob Lourenço and Cristiane Kibune Nagasako Vieira da Cruz and Glaucia Fernanda Soares Rupert Reis and Livia Bitencourt Pascoal and Juliana Delgado Campos Mello and Isabela Machado Pereira and Millene Leal Nascimento and Priscilla De Sene Portel Oliveira and Ligiana Pires Corona and Maria de Lourdes Setsuko Ayrizono and Carmen Silvia Passos Lima and Raquel Franco Leal},

doi = {10.1177/03946320251319379},

issn = {2058-7384},

year  = {2025},

date = {2025-01-00},

urldate = {2025-01-00},

journal = {Int J Immunopathol Pharmacol},

volume = {39},

publisher = {SAGE Publications},

abstract = {<jats:p> Crohn’s disease (CD) involves immune system interactions with intestinal tissue, driven by pro-inflammatory cytokines like Tumor Necrosis Factor (TNF-α). Adalimumab, targeting TNF-α, regulates associated inflammatory responses. Despite being humanized, it may induce immunogenic processes, affecting treatment effectiveness. Thus, monitoring serum adalimumab and anti-drug antibody (ADA) levels can optimize therapy. Understanding genetic factors influencing adalimumab response can enhance personalized treatment and improve patient quality of life. We aimed to quantify adalimumab serum levels, assess test interchangeability, detect ADA, examine immune complex formation, and investigate genetic phenotypes related to immunogenicity in CD patients. Seventy CD patients in the maintenance phase with adalimumab were classified into active (CDA) and remission (CDR) groups. Adalimumab concentration was determined via enzyme-linked immunosorbent assay (ELISA—Promonitor) and lateral flow assay (Quantum Blue), with assay interchangeability assessed statistically. ADA and immune complex formation were quantified using ELISA assays. DNA was genotyped for the genes ATG16L1, CD96, and CD155. No significant differences in adalimumab serum concentrations were observed between groups, regardless of the assay. However, a statistical difference between the tests indicated measurement disparity ( P = 0.003), with moderate agreement (Lin’s correlation of 0.247). ADA was detected in 4 of 27 of the patients with infratherapeutic levels, 3 in the CDA group and 1 in the CDR group. Analysis of immune complexes revealed significantly higher concentrations in the CDA group ( P = 0.0125). The genotypic evaluation revealed significant associations for the CD96 CC (wild-type) genotype with higher CRP levels, colonic involvement, and infratherapeutic levels of adalimumab. ATG16L1 CC genotype was associated with higher CDEIS and fecal calprotectin values, while the variant (TT) genotype had lower platelet counts. The effectiveness of treatment with adalimumab was not directly related to higher medication levels in this cohort. The disparity between tests indicates the need to use only one test in patient follow-up to ensure accuracy in therapeutic monitoring. Genotypic differences highlight the correlation between the wild genotype for CD96 and ATG16L1 with unfavorable laboratory and endoscopic response to adalimumab. Finally, the more significant levels of immune complexes in the CDA group indicate an association with a worse response to adalimumab. </jats:p>},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Liveraro2025,

title = {Improving resectable gastric cancer prognosis prediction: A machine learning analysis combining clinical features and body composition radiomics},

author = {Gianni S.S. Liveraro and Maria E.S. Takahashi and Fabiana Lascala and Luiz R. Lopes and Nelson A. Andreollo and Maria C.S. Mendes and Jun Takahashi and José B.C. Carvalheira},

doi = {10.1016/j.imu.2024.101608},

issn = {2352-9148},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {Informatics in Medicine Unlocked},

volume = {52},

publisher = {Elsevier BV},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Padilha2024,

title = {Subcutaneous adipose tissue radiodensity: An emerging risk factor for severe COVID-19},

author = {Daniela M.H. Padilha and Maria C.S. Mendes and Maria E.S. Takahashi and Fabiana Lascala and Marina N. Silveira and Lara Pozzuto and Larissa A.O. Carrilho and Lívia D. Guerra and Rafaella C.L. Moreira and Sandra R. Branbilla and Celso Darío Ramos and José B.C. Carvalheira},

doi = {10.1016/j.nut.2024.112561},

issn = {0899-9007},

year  = {2024},

date = {2024-12-00},

urldate = {2024-12-00},

journal = {Nutrition},

volume = {128},

publisher = {Elsevier BV},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}

@article{Carron2024b,

title = {The impact of ERP29 on the progression of pharyngeal squamous cell carcinoma},

author = {Juliana Carron and Lilian de Oliveira Coser and Carmen Silvia Passos Lima and Gustavo Jacob Lourenço},

doi = {10.1038/s41598-024-76210-6},

issn = {2045-2322},

year  = {2024},

date = {2024-12-00},

urldate = {2024-12-00},

journal = {Sci Rep},

volume = {14},

number = {1},

publisher = {Springer Science and Business Media LLC},

keywords = {Área Clínica},

pubstate = {published},

tppubtype = {article}

}